CN102413816A - 苯达莫司汀的口服制剂 - Google Patents

苯达莫司汀的口服制剂 Download PDF

Info

Publication number
CN102413816A
CN102413816A CN2010800183962A CN201080018396A CN102413816A CN 102413816 A CN102413816 A CN 102413816A CN 2010800183962 A CN2010800183962 A CN 2010800183962A CN 201080018396 A CN201080018396 A CN 201080018396A CN 102413816 A CN102413816 A CN 102413816A
Authority
CN
China
Prior art keywords
polyethylene glycol
pharmaceutical compositions
aqueous pharmaceutical
aqueous
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800183962A
Other languages
English (en)
Chinese (zh)
Inventor
拉切尔·Y·拉贝尔
皮尤什·R·帕泰尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon LLC filed Critical Cephalon LLC
Publication of CN102413816A publication Critical patent/CN102413816A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2010800183962A 2009-04-28 2010-04-01 苯达莫司汀的口服制剂 Pending CN102413816A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17342309P 2009-04-28 2009-04-28
US61/173,423 2009-04-28
PCT/US2010/029578 WO2010126676A1 (en) 2009-04-28 2010-04-01 Oral formulations of bendamustine

Publications (1)

Publication Number Publication Date
CN102413816A true CN102413816A (zh) 2012-04-11

Family

ID=42174186

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800183962A Pending CN102413816A (zh) 2009-04-28 2010-04-01 苯达莫司汀的口服制剂

Country Status (7)

Country Link
US (1) US20120157505A1 (enExample)
EP (1) EP2424506A1 (enExample)
JP (1) JP2012525387A (enExample)
CN (1) CN102413816A (enExample)
CA (1) CA2760085A1 (enExample)
MX (1) MX2011011109A (enExample)
WO (1) WO2010126676A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105726472A (zh) * 2016-03-25 2016-07-06 南京康玻斯医药科技有限公司 苯达莫司汀药剂组合物及应用
CN109953954A (zh) * 2013-08-27 2019-07-02 V·沃道里斯 苯达莫司汀医药组合物
CN110123747A (zh) * 2019-04-26 2019-08-16 嘉兴市爵拓科技有限公司 苯达莫司汀的制剂

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP3158991B1 (en) * 2010-01-28 2021-03-17 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
WO2011151087A1 (en) * 2010-06-02 2011-12-08 Astellas Deutschland Gmbh Oral dosage forms of bendamustine
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
CN102125693A (zh) * 2011-01-25 2011-07-20 福建科瑞药业有限公司 一种盐酸噻加宾药物组合物及其制备方法
WO2013123227A1 (en) * 2012-02-14 2013-08-22 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
HUE064884T2 (hu) 2012-03-20 2024-04-28 Eagle Pharmaceuticals Inc Bendamusztin kiszerelések
ES2718902T3 (es) 2012-03-20 2019-07-05 Eagle Pharmaceuticals Inc Composición líquida destinada a ser utilizada en un método de tratamiento de condiciones en respuesta a la bendamustina en pacientes que requieren volúmenes reducidos para administración
EP2641592A1 (en) * 2012-03-23 2013-09-25 Salmon Pharma GmbH Pharmaceutical formulation comprising bendamustine
US9320730B2 (en) 2014-03-13 2016-04-26 Vasilios Voudouris Bendamustine solid dispersions and continuous infusion
US20200246312A1 (en) 2017-10-05 2020-08-06 Tube Pharmaceuticals Gmbh Oral bendamustine formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD159289A1 (de) * 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
US20060128777A1 (en) * 2004-11-05 2006-06-15 Bendall Heather H Cancer treatments
WO2006076620A2 (en) * 2005-01-14 2006-07-20 Cephalon, Inc. Bendamustine pharmaceutical compositions for lyophilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159289C (enExample) * 1903-10-08 1905-03-16
DE10306724A1 (de) 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
CN101219113A (zh) * 2008-01-28 2008-07-16 济南帅华医药科技有限公司 含苯达莫司汀的复方抗癌缓释注射剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD159289A1 (de) * 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
US20060128777A1 (en) * 2004-11-05 2006-06-15 Bendall Heather H Cancer treatments
WO2006076620A2 (en) * 2005-01-14 2006-07-20 Cephalon, Inc. Bendamustine pharmaceutical compositions for lyophilisation

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109953954A (zh) * 2013-08-27 2019-07-02 V·沃道里斯 苯达莫司汀医药组合物
CN105726472A (zh) * 2016-03-25 2016-07-06 南京康玻斯医药科技有限公司 苯达莫司汀药剂组合物及应用
CN105726472B (zh) * 2016-03-25 2019-12-13 南京康玻斯医药科技有限公司 苯达莫司汀药剂组合物及应用
CN110772480A (zh) * 2016-03-25 2020-02-11 南京康玻斯医药科技有限公司 苯达莫司汀药剂组合物及应用
CN110772480B (zh) * 2016-03-25 2022-05-17 南京百劲企业管理咨询有限公司 苯达莫司汀药剂组合物及应用
CN110123747A (zh) * 2019-04-26 2019-08-16 嘉兴市爵拓科技有限公司 苯达莫司汀的制剂

Also Published As

Publication number Publication date
WO2010126676A1 (en) 2010-11-04
JP2012525387A (ja) 2012-10-22
US20120157505A1 (en) 2012-06-21
EP2424506A1 (en) 2012-03-07
CA2760085A1 (en) 2010-11-04
MX2011011109A (es) 2011-11-18

Similar Documents

Publication Publication Date Title
CN102413816A (zh) 苯达莫司汀的口服制剂
EP2451438B1 (en) Pharmaceutical composition for a hepatitis c viral protease inhibitor
US10543196B2 (en) Oral dosage forms of bendamustine
US20040092428A1 (en) Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
DK2575784T3 (en) ORAL DOSAGE FORMS OF BENDAMUSTIN
US8673351B2 (en) Crystallization inhibitor and its use in gelatin capsules
US20050107438A1 (en) Pharmaceutical composition comprising 3-[(2-{[4-(Hexyloxycarbonylaminoiminomethyl) phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester or a salt therefore
EP2600839B1 (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine
EP1922061B1 (en) Oral solid pharmaceutical formulation of the tribulin inhibitor indibulin
US10117939B2 (en) Pharmaceutical compositions comprising nebivolol or a nebivolol analogue
JP2018530597A (ja) フルベストラント組成物
ES2869197T3 (es) Formulaciones que contienen domperidona
US20210369615A1 (en) Solid oral formulations of amphotericin b
HK1161081A (en) Oral dosage forms of bendamustine
HK1120739B (en) Oral solid pharmaceutical formulation of the tribulin inhibitor indibulin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120411